# Capacity and site readiness for hypertension control program implementation in Nigeria: A nationwide cross-sectional study

**Authors:** Innocent Ijezie Chukwuonye, Ejiroghene Martha Umuerri, Abigail Baldridge, Yekeen Ayodele Ayoola, Mahmoud Umar Sani, Okechukwu Samuel Ogah, Olanike Allison Orimolade, Miracle Erinma Chukwuonye, Kalu Ulu Kalu, Caleb Ogechi Raphael, Nyemike Simeon Awunor, Obatavwe Ukoba, Felicity Chinyere Odoh, Henry Ifeanyichukwu Okolie, Mustapha Abdulsalam Danimoh, Apollos Daniel, Usman Muhammad Ibrahim, Sabiu Mohammed Hamza, Oluwatosin Zinnat Makinde, Adeyemi Sunday Adewole, Dike Bevis Ojji, Mark D. Huffman

PMC · DOI: 10.1371/journal.pone.0344011 · PLOS One · 2026-03-13

## TL;DR

This study assesses if Nigerian healthcare centers are ready to implement a hypertension control program, finding they have basic resources but lack training and protocols.

## Contribution

The study provides the first large-scale assessment of hypertension program readiness in Nigerian primary healthcare facilities.

## Key findings

- Most PHCs have basic equipment like blood pressure apparatus but lack treatment guidelines and protocols.
- Only 66% of PHCs had at least one 30-day antihypertensive treatment regimen in stock.
- Electronic patient records are widely used, but training and protocol provision are critical gaps.

## Abstract

The aim of this study is to determine the capacity and readiness of Nigerian primary healthcare facilities to adopt a multi-level approach for the diagnosis, treatment, and control of hypertension.

Using a multi-stage sampling technique, 5 states were selected for the nationwide study, and 10 Primary Healthcare Centres (PHCs) were selected from each of the participating states. The 50 PHCs were evaluated using the World Health Organization-modified Service Availability and Readiness Assessment, focusing on the diagnosis and treatment of hypertension in Nigeria. The indicator scores for general and cardiovascular service preparedness were computed using the proportion of PHCs with accessible facilities, tools, diagnostic guidelines, and prescription drugs.

A majority of PHCs (n = 43; 86%) reported having two or more full-time staff. The median number of full-time employees for the 50 PHCs was 6 (IQR = 2–9), and for the community health extension workers (CHEWs), the median was 2, the interquartile range (IQR) = 0–4. None of the PHCs had full-time physicians. Ninety-eight percent, 94%, and 84% of the 50 PHCs are able to provide screening services, diagnose, and confirm hypertension, respectively. In addition, 98% of the PHCs had functional blood pressure apparatus. However, only a minority of PHCs had the guidelines (24%), treatment algorithms (27%), and facilities. Most of the 50 PHCs (96%) use electronic patient records in their respective centres. Of the 50 PHCs studied, 66% had at least one 30-day antihypertensive treatment regimen in stock. The most commonly available drug classes were calcium channel blockers (72%), followed by diuretics (42%), central acting agents (38%), and angiotensin-converting enzyme inhibitors (36%). The median number of 30-day regimens in stock was 15 (IQR 0–132).

This first large-scale systematic assessment of capacity and readiness for a system-level hypertension control program within five states of Nigeria demonstrated implementation feasibility based on the workforce, equipment, and health information systems, but there is a critical need for health-worker training and provision of protocols for hypertension treatment and control, as well as some need to strengthen the essential medicine supply chain.

## Full-text entities

- **Diseases:** renal failure (MESH:D051437), -communicable diseases (MESH:D003141), Hypertension (MESH:D006973), coronary artery disease (MESH:D003324), Cardiovascular Disease (MESH:D002318), death (MESH:D003643), stroke (MESH:D020521), infection (MESH:D007239)
- **Chemicals:** spironolactone (MESH:D013148), thiazide (MESH:D049971), furosemide (MESH:D005665), blood pressure-lowering medications (-)
- **Species:** Homo sapiens (human, species) [taxon 9606], Human immunodeficiency virus 1 (no rank) [taxon 11676]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12987462/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12987462/full.md

## References

38 references — full list in the complete paper: https://tomesphere.com/paper/PMC12987462/full.md

---
Source: https://tomesphere.com/paper/PMC12987462